undamentalytics Newsletter

Regeneron Pharmaceuticals number of employees

Regeneron Pharmaceuticals reported 15,410 employees at December 31, 2025 in its latest annual report, up 304 (2.0%) on the year before. That compares with 10,368 at December 31, 2021. Revenue per employee was $930,753.

Headcount by year

Fiscal year endEmployeesChangeRevenue per employeeSource
December 31, 2025 15,410 +304 (2.0%) $930,753 10-K, filed February 4, 2026
December 31, 2024 15,106 +1,656 (12.3%) $940,156 10-K, filed February 5, 2025
December 31, 2023 13,450 +1,599 (13.5%) $975,257 10-K, filed February 5, 2024
December 31, 2022 11,851 +1,483 (14.3%) $1.0m 10-K, filed February 6, 2023
December 31, 2021 10,368 — $1.6m 10-K, filed February 7, 2022

What the annual reports say

  • Workforce Profile As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries (primarily in the United Kingdom, Ja 2025 annual report
  • Employee Profile As of December 31, 2024, we had 15,106 full-time employees, consisting of 11,914 employed in the United States, 2,168 employed in Ireland, and 1,024 employed in other countries (primarily in the United Kingdom, Japan, and Germany). 2024 annual report
  • Employee Profile As of December 31, 2023, we had 13,450 full-time employees, consisting of 10,875 employed in the United States, 1,939 employed in Ireland, and 636 employed in other countries (primarily in the United Kingdom, Japan, and Germany). 2023 annual report
  • Employee Profile As of December 31, 2022, we had 11,851 full-time employees, consisting of 9,843 employed in the United States, 1,721 employed in Ireland, and 287 employed in other countries (primarily in the United Kingdom and Germany). 2022 annual report
  • Employee Profile As of December 31, 2021, we had 10,368 full-time employees, consisting of 8,564 employed in the United States, 1,648 employed in Ireland, and 156 employed in other countries (including the United Kingdom, Germany, the Netherlands, and Canada). 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: REGN vs VRTXBIIB vs REGNGILD vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regeneron Pharmaceuticals.